Most of the world's research-grade peptides come from a relatively small number of synthesis facilities, almost all of them in mainland China. The reasons are economic (lower cost of Fmoc-amino-acid building blocks and SPPS-grade solvents), technical (decades of accumulated expertise in solid-phase peptide synthesis), and logistical (well-developed export infrastructure through Shanghai and Hong Kong).

This concentration is good for buyers in terms of cost and quality — the best Chinese facilities rival or exceed anything in the US or Europe — but it creates supply-chain fragility if you don't know who you're really buying from. The peptide in your vial may have come from a top-tier synthesis house, or it may have come from a relabeler who buys crude peptide, dissolves it, filters it, and ships it as if they made it.

This article explains how to tell the difference.

What a synthesis facility actually looks like

A genuine peptide synthesis facility has certain irreducible characteristics:

• Synthesis capacity: Multiple SPPS reactors (also called peptide synthesizers) at multiple scales — typically 50 mmol to 200 mmol reactors for research-scale work, plus 1L to 20L reactors for kilo-scale production. Each reactor is a sophisticated piece of equipment that costs $50K to $500K.
• Fmoc-amino-acid inventory: The facility maintains an inventory of 50-200 protected amino acid building blocks, kept under nitrogen in a cold room. Each building block has a CoA from the supplier (typically Bachem, Iris Biotech, or a Chinese equivalent).
• HPLC purification: Multiple preparative HPLC systems for crude-peptide purification. A research-scale facility needs at least 2-4 preparative HPLCs to handle concurrent projects.
• Lyophilisation: Benchtop freeze dryers for research batches, larger production-scale freeze dryers for kilo lots.
• QC lab: Analytical HPLC, mass spec (typically ESI-MS or MALDI-TOF), peptide synthesizers (for QC re-synthesis if needed), amino acid analysis.
• Cold storage: Walk-in freezers (-20°C) for bulk peptide, smaller -80°C units for analytical samples.

If your vendor can't describe this kind of facility — or if the facility they describe doesn't match what you see in photos or during a visit — they're likely a relabeler or a trading company rather than a synthesis house.

SPPS vs LPPS: the synthesis chemistry

Solid-Phase Peptide Synthesis (SPPS) is the standard method for research and kilo-scale peptide production. The C-terminal amino acid is attached to a resin bead, then amino acids are added one at a time through cycles of deprotection and coupling. SPPS works well for peptides up to ~50 residues and is the dominant method used by all reputable synthesis facilities.

Liquid-Phase Peptide Synthesis (LPPS) is older and rarer; used mainly for very short peptides (<10 residues) at kilo+ scale. Native Chemical Ligation (NCL) is used for very long or difficult peptides (>50 residues) by combining two SPPS-made fragments. Most research vendors should be using SPPS for everything they sell.

Certifications that matter — and ones that don't

ISO 9001 is a quality management system certification. It's table stakes — every legitimate facility has it. It tells you the facility has documented processes for handling complaints, training staff, and managing records. It does NOT tell you anything about the quality of the actual peptide.

ISO 13485 is the medical-device quality management standard. More rigorous than ISO 9001; required for facilities making IVD-grade products. Having ISO 13485 is a positive signal but doesn't apply to most research peptide because research peptide is not classified as IVD.

GMP (Good Manufacturing Practice) is the pharmaceutical-grade quality system, codified in ICH Q7 for active pharmaceutical ingredients. GMP is the gold standard, but it is also expensive and time-consuming to maintain. Most research peptide is made under "GMP-aligned" workflows rather than full GMP certification. This is appropriate — full GMP is required for clinical-grade material, not for research reagent.

DMF (Drug Master File) is a confidential document filed with FDA that allows a manufacturer to reference their manufacturing process in a customer's drug application. Chinese facilities with USDMF eligibility (meaning their CoAs and processes meet FDA standards) are the gold standard for anyone whose peptide might eventually be used in a US clinical trial. USDMF-eligibility is rare and a strong signal of quality.

The relabeler problem

A relabeler (or "trading company") buys crude or partially-purified peptide in bulk from a synthesis house, dissolves it in their own facility, often with inadequate QC, and ships it under their own brand. The peptide in the vial may have come from a legitimate synthesis house, or it may have come from a less reputable source. The relabeler typically does not know which synthesis house made any given batch, and has limited ability to investigate quality issues.

Relabelers can offer competitive prices because they skip the most expensive steps (synthesis, primary purification). They cannot offer the same quality assurance because they have no visibility into the upstream process.

How to tell: Ask the vendor for the synthesis house's name, location, and ideally a tour or audit. If they refuse, or if the answer is vague ("we source from multiple facilities"), they're probably a relabeler. Helix publishes the names of our three primary synthesis facilities on our Sourcing section, including the city and ISO certification status of each. This level of transparency is unusual in the industry; that's deliberate.

Custom peptide orders

If you need a peptide that isn't in stock (a non-standard sequence, a modified amino acid, an isotope-labelled variant), the same supplier-evaluation framework applies. A legitimate synthesis facility will:

• Quote you based on length, scale, and purification level (crude, ≥85%, ≥95%, ≥98%)
• Give you a realistic timeline (research-scale: 4-8 weeks; kilo-scale: 3-6 months)
• Offer to send a small analytical sample before committing to a full order
• Provide full CoA documentation including HPLC, MS, and any other assays relevant to your peptide

Red flags for custom orders: promises of "GMP-grade peptide in 7 days," quotes that are 30-50% below market, refusal to provide a sample, or contracts that don't specify the analytical deliverables.

The audit question

If you're a procurement officer evaluating a peptide vendor, the strongest possible signal is a willingness to be audited. A legitimate synthesis facility will let you (or a third-party inspector) visit their site and verify their claims. Relabelers will not, because there's nothing to audit beyond their office.

Helix publishes its primary and secondary supplier names because we believe that the buyer's ability to verify provenance is the single most important trust signal in this industry. If you're evaluating us, we'd rather you visit our primary synthesis facility in Hangzhou and confirm the claims than take our word for it.

---

Helix operations and procurement team. Sourcing partners listed on the Sourcing section of helix.bio.